Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.
What happened
FDA inspected the Saint-Laurent, Quebec contract manufacturing site from August 14 to 18, 2023 and found the company released drug components without testing each lot for identity, instead trusting suppliers' certificates of analysis (COA, the supplier's own report of test results). Inspectors also found the manufacturing process had never been validated, that the quality unit did not carry out its duties, and that similar problems had been cited at earlier inspections. FDA placed the firm on Import Alert 66-40 on January 26, 2024, which means its shipments can be stopped at the U.S. border without inspection.
What FDA found
The firm did not test each incoming lot of each ingredient to confirm what it was, and accepted supplier test reports without ever checking that those suppliers' results were reliable.
21 CFR 211.84Each lot of glycerin went untested for identity, even though glycerin can carry diethylene glycol (DEG) and ethylene glycol (EG), chemicals that have caused fatal poisonings worldwide; the glycerin was used in pediatric products.
21 CFR 211.84The firm never validated its manufacturing process, including for products for infants and children, and told inspectors it did not know this was required.
21 CFR 211.100(a)The quality unit, the group responsible for signing off on quality, failed to ensure yearly product reviews and to confirm that outside testing labs were qualified.
21 CFR 211.22 and 211.180(e)Master production records and batch records were missing required elements, including documentation that each significant manufacturing step was carried out.
21 CFR 211.186 and 211.188(b)
What FDA wants
FDA asks the company to reply in writing within 15 working days describing fixes and prevention steps, and to supply DEG and EG test results for all high-risk ingredient lots within 30 calendar days, plus a full risk assessment, validation plans, quality unit remediation and, if it wants to resume U.S. sales, a qualified CGMP consultant.
Who should pay attention
- brands that hire this contract manufacturer to make their homeopathic drugs
- distributors and retailers selling homeopathic products made at this site
- companies buying its bulk drug product containers for repackaging
This is a summary. Read the original letter on fda.gov.